Dr. Scot Ebbinghaus joined Merck Research Labs Late-Stage Oncology Development in 2007. He is currently Vice President and Therapeutic Area Head for Late-Stage Oncology Development. Dr. Ebbinghaus has played key roles in the development of the lead indication for KEYTRUDA® in melanoma, the subsequent development of KEYTRUDA® across multiple indications, and the development of LYNPARZA®, LENVIMA®, KOSELUGO®, and WELIREG® across multiple indications. These important and approved oncology drugs have been prescribed to nearly 2 million patients with cancer worldwide. Dr. Ebbinghaus is currently responsible for overseeing the development of multiple late-stage assets in the Merck Oncology portfolio and strategic alliances, including multiple antibody drug conjugates in late development, V940, the investigational individualized neoantigen therapy (INT), MK-1084, an investigational KRAS G12C inhibitor, and IO-IO coformulations with pembrolizumab and vibostolimab (anti-TIGIT antibody), favezelimab (anti-LAG-3 antibody) and quavonlimab (anti-CTLA4 antibody). Dr. Ebbinghaus co-chairs the joint development committees in strategic alliances with Astra Zeneca, Daiichi-Sankyo, and Moderna. Dr. Ebbinghaus oversees the development teams responsible for the development of Merck’s assets in melanoma and in pediatric tumors. Prior to joining Merck, Dr. Ebbinghaus was an Associate Professor at the University of Arizona in the Department of Medicine, Section of Hematology/Oncology. Dr. Ebbinghaus earned his M.D. degree from the University of Missouri-Kansas City, completed his residency in Internal Medicine and his fellowship in Hematology Oncology at the University of Alabama-Birmingham. Dr. Ebbinghaus has published over 60 manuscripts, and 5 book chapters in the field of Oncology. In addition to current responsibilities at Merck, Dr. Ebbinghaus is an attending physician at Fox Chase Cancer Center in Philadelphia in the Thoracic Oncology unit.